NAUTILUS Study | RNS® System Responsive Thalamic Stimulation for IGE

Skip to main content
NeuroPace, Inc
  • Patients
  • Providers
  • About Us
  • nSight
  • PDMS
  • Learn About the RNS System
    • Drug-Resistant Epilepsy
    • The RNS System
  • See if you Qualify
    • Take the Quiz
    • Find a Center
  • Preliminary NAUTILUS Results
  • Hear from Patients
    • Patient Stories
    • How Data Helped
    • RNS Community Chat
  • Resources
    • Find a Center
    • RNS Community Chat
    • Education (brochures, infographics, videos)
    • Helpful Links
    • Clinical Trials
    • Contact Us
  • Blog
  • Current Patients
    • Manuals
    • MRI Safety
    • How-to Videos
    • Living with the RNS System
    • Current Patient FAQ
  • Learn About the RNS System
    • Drug-Resistant Epilepsy
    • The RNS System
  • See if you Qualify
    • Take the Quiz
    • Find a Center
  • Preliminary NAUTILUS Results
  • Hear from Patients
    • Patient Stories
    • How Data Helped
    • RNS Community Chat
  • Resources
    • Find a Center
    • RNS Community Chat
    • Education (brochures, infographics, videos)
    • Helpful Links
    • Clinical Trials
    • Contact Us
  • Blog
  • Current Patients
    • Manuals
    • MRI Safety
    • How-to Videos
    • Living with the RNS System
    • Current Patient FAQ
Press enter to begin your search
Notification

The RNS® System was granted a Breakthrough Device Designation by the FDA for assessment in Idiopathic Generalized Epilepsy

Learn more
THE RNS® System Nautilus Study

Committed to Life-Changing Outcomes

Preliminary 18-month safety and effectiveness results of RNS System responsive thalamic stimulation for the treatment of idiopathic generalized epilepsy (IGE)1

CAUTION Investigational device. Limited by U.S. law to investigational use for Idiopathic Generalized Epilepsy.

Meaningful Seizure Reduction

The NAUTILUS Study is the first and only neuromodulation randomized controlled trial (RCT) to demonstrate a statistically significant reduction in GTCs (Generalized Tonic-Clonic Seizures) for IGE patients2

77%
Median Reduction in GTCs
at 18-months
n=40 (p<0.001)

This reduction in GTCs was highly correlated with physician and patient Clinical Global Impression of Change

Clinical Global Impression of Change - Global Improvement

Breakthrough Evidence

The NAUTILUS study is the first-and-only RCT to demonstrate that IGE seizures can be safely detected and treated in the centromedian (CM) nucleus

Checkmark
Met Primary Safety
Endpoint
23
Sites across the
United States
87
Patients implanted
Icon

Breakthrough Device Designation

NeuroPace received an FDA Breakthrough Device Designation to study the treatment of drug-resistant IGE with the RNS system. This program is designed to accelerate access to treatment for patients with life-threatening conditions.

See the 18-month preliminary results.

See the data for yourself.

SEE THE DATA
Image in support of the 18-month preliminary results

NAUTILUS STUDY News & Updates

NeuroPace Announces Preliminary Results from 18-month Data

December 8, 2025

NeuroPace Announces Preliminary Results from 18-month Data

NeuroPace Announces Preliminary Results from 18-month Data in NAUTILUS Study

Read more
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

December 21, 2023

Early Completion of Patient Enrollment

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Read more
First Patient Implanted in NAUTILUS Study

October 11, 2022

First Patient Implanted in NAUTILUS Study

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

Read more
Breakthrough Device Designation

March 31, 2021

Breakthrough Device Designation

The RNS System has been granted a Breakthrough Device Designation by the FDA to accelerate assessment and access for the treatment of drug-resistant IGE

Read more
NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

November 10, 2021

NeuroPace Receives IDE Approval

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

Read more

Stay up to date on the latest IGE developments

Follow us on social media:
NeuroPace on X NeuroPace on LinkedIn
  1. Preliminary Safety and Effectiveness of RNS System Responsive Thalamic Stimulation for Treatment of IGE with GTCs: 18-Month Data, American Epilepsy Society, Dec 2025.
  2. Pre-specified additional effectiveness endpoint compared to baseline; pre-specified primary effectiveness not significant

CAUTION Investigational device. Limited by U.S. law to investigational use for Idiopathic Generalized Epilepsy. This preliminary clinical data is being shared for educational and scientific purposes only. The RNS System is not FDA approved for treatment of IGE.

®2025 NeuroPace, Inc. All rights reserved. NeuroPace and RNS are registered trademarks of NeuroPace, Inc., Mountain View, CA 94043. NP250142 Rev1 Date 2025-11

  • Safety Information
  • Legal
  • Privacy Policy
1-866-726-387624-hr Support Line

PATIENTS

  • Drug-Resistant Epilepsy
  • The RNS System
  • Hear from Patients
  • Is It Right for You?
  • Current Patients
  • Resources

PROVIDERS

  • Product
  • Clinical Benefits
  • Actionable Insights
  • Patient Selection
  • Education & Training
  • Resources

CORPORATE

  • In The News
  • Press Releases
  • Leadership
  • Careers
  • Contact Us
  • FCOI Procedure

  • PATIENTS

    Safety

  • PROVIDERS

    Legal

  • INVESTORS

    Privacy Policy

  • CORPORATE

1-866-726-3876 24-hr Support Line

© 2026 NeuroPace, Inc.

Step 1 of 7

14%
    The RNS System is for individuals 18 and older who have focal epilepsy and have tried two or more medications without finding seizure control.

  • Based on your answers, your patient might benefit from the RNS System.

    Get your profile and a list of questions to ask your doctor.

  • Unfortunately it appears your patient is not an appropriate candidate for the RNS® System at this time.

  • The RNS® System is intended for patients who have undergone diagnostic testing that localized no more than 2 epileptogenic foci.

    If your patient has not undergone diagnostic testing, search here to find a comprehensive epilepsy center that can evaluate your patient, including determining if the RNS System is right for them.

  • If you are interested in learning more about the RNS® System, you can have an RNS® System professional contact you by filling out the form below:

  • By filling out this form, you are agreeing to the terms of our privacy policy. This form is intended for US residents only.

    By clicking submit, you are agreeing to receive communications from NeuroPace. You can unsubscribe at any time.

    * Required fileds

Share your Story: Terms and conditions

By filling out the form and submitting your story (and/or photograph), you are agreeing to the following:

  1. NeuroPace may review the information and any photographs you provide for potential publication on our website.
  2. If NeuroPace decides to use your story, we will contact you and ask you to sign a release for a version of your story to be used on the NeuroPace website, Facebook, Instagram, Twitter and/or LinkedIn. Unless you sign the release, we will not publish the story, your name, or the photographs you provided.
  3. Regardless of whether we publish your story, we will add your name and e-mail address to the NeuroPace email list to hear from us about product updates, upcoming events and other relevant information. We will not sell your information to third parties. 
  4. Our use of your information is subject to our Privacy Policy, which you can access here.
neuropace logoLogo Header Menu
  • Patients
  • Providers
  • Corporate
  • Investors
  • nSight
  • PDMS
  • Take the Quiz
  • Clinical Trials